Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corp ADR (NQ: LEGN )

42.69 +1.75 (+4.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corp ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >
No Early Relief for JW Therapeutics from Cancer Wonder Drug
Key Takeaways: JW Therapeutics prices its new cancer therapy at around a million yuan, with the high production costs hard to bring down.  Large-scale market expansion is not going to be easy  The... 
Via Benzinga
Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90
On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier. 
Via Investor's Business Daily
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
NexImmune Pauses Developing Multiple Myeloma Hopeful, Citing Competition
NexImmune Inc (NASDAQ: NEXI) cited the competitive environment in the blood cancer space as the reason for  
Via Benzinga
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022
From Legend Biotech Corporation
Via Business Wire
Short Volatility Alert: Legend Biotech Corporation
On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went up +6.97% to $51.10. The... 
Via Benzinga
Legend Biotech Shares Move Higher After Bullish BMO Pitch
Via Benzinga
Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
From Legend Biotech
Via Business Wire
Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking
CSPC Pharma out-licensed global rights for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment and up to $148... 
Via Talk Markets
PayPal, Alphabet And Some Other Big Stocks Recording Gains On Wednesday
U.S. stocks closed sharply higher on Wednesday, with the Dow Jones jumping more than 400 points. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
Short Volatility Alert: Legend Biotech Corporation
On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went down -1.38% to $42.96. The... 
Via Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Walmart, Shopify And Some Other Big Stocks Recording Losses On Tuesday
U.S. stocks closed lower on Monday, with the Nasdaq Composite dropping more than 200 points. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
Legend Biotech Corporation Announces Pricing of Public Offering
From Legend Biotech Corporation
Via Business Wire
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers 
Via Benzinga
Legend Biotech Corporation Announces Proposed Public Offering
From Legend Biotech Corporation
Via Business Wire
How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer
This biotech stock launched in February to work on CAR-T treatments. 
Via Investor's Business Daily
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma
From Legend Biotech
Via Business Wire
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers
From Legend Biotech
Via Business Wire
Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights
From Legend Biotech
Via Business Wire
Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Legend Biotech
Via Business Wire
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and... 
Via Talk Markets
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
From Legend Biotech
Via Business Wire
Legend Biotech Appoints Lori Macomber as Chief Financial Officer
From Legend Biotech
Via Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Legend Biotech Announces Appointment of Global Head of Research and Early Development
From Legend Biotech Corporation
Via Business Wire
HFCAA News: 128 Chinese Stocks the SEC Could Delist
The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.